

SAPPHIRE Study Update – Piedmont Healthcare confirmed as participant in study

Protocol for SAPPHIRE Study to be finalised with additional U.S. Study participants

PERTH, Australia, 25 August 2025: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to provide an update on the progress of the upcoming U.S. multi-centre, clinical, SAPPHIRE Study in collaboration with leading U.S. hospital systems, with Piedmont Healthcare agreeing to be the first Study participant, subject to final documentation and ethics approval.

Highlights

- **First SAPPHIRE Study collaborator secured – leading U.S. health systems confirmed in-principal participation, subject to contracting and ethics approval**
- **Piedmont Healthcare to be among the first U.S. health systems participating in the Study**
- **Study to run over three phases, evaluating coronary artery disease risk using the Salix® Coronary Plaque module, followed by Artrya's novel Plaque Dispersion Score (PDS)**
- **Strong focus on coronary artery disease in women, addressing a significant unmet need – 64% of women¹ who die from coronary artery disease show no prior symptoms**
- **Study designed to generate robust clinical evidence to support broader clinical and commercial adoption of Salix® in the U.S.**

John Konstantopoulos, Co-Founder and CEO of Artrya commented:

"We are excited to be able to announce that Piedmont Healthcare has agreed to be a participant in the SAPPHIRE Study. The Piedmont Heart Institute is a centre of excellence known for clinical innovation and we are thrilled to have Piedmont join this seminal study.

We expect that the SAPPHIRE Study will commence early in CY26 as we move through the contracting and ethics processes. We believe the Study will deliver robust clinical evidence to support broader adoption of Salix® and validate our plaque and PDS as a new approach to assessing coronary artery disease risk and management of this disease. We also aim to make major advances in women's health with coronary artery disease poorly managed and causing the deaths of 1 in 3 women²."

Venkat Polsani, MD, Chief of Cardiovascular Imaging Center of Excellence for Piedmont Healthcare said:

"The SAPPHIRE Study represents a major step forward in how we identify and manage coronary artery disease. Traditional diagnostic tools offer limited precision at the individual level. Artrya's technology, especially the Plaque Dispersion Score, holds the promise of transforming risk assessment by focusing on the characteristics of plaque that truly matter. We're excited to be part of this initiative and look forward to the insights it will bring to clinical practice."

SAPPHIRE Study design current being finalised

The **Salix®-based Analysis of Plaque to Identify Patients at Higher Risk of Events (SAPPHIRE)** Study is a retrospective, multi-centre, real-world study conducted in 3-phases. The study is designed to evaluate the prognostic and clinical utility of Artrya's Salix® Plaque Analysis and the Plaque Dispersion Score (**PDS**). These AI-powered tools aim to identify high-risk coronary artery disease patients with greater precision than traditional risk models. A more accurate assessment requires the analysis of individual plaque features, which is impractical for human readers of CCTA scans, but can be enabled using AI platforms.

¹ Comprehensive plaque assessment by coronary CT angiography. Nat Rev Cardiol 11, 390–402 (2014)

² American Heart Association – Go Red for Women – The Facts About Women and Heart Disease

The first Study participant is Piedmont Healthcare, based in Atlanta, Georgia, who are nationally recognised for leadership in heart and vascular services through the Piedmont Heart Institute, a centre of excellence known for clinical innovation and integrated cardiovascular care. Piedmont's expertise in advanced imaging and interventional cardiology makes it an ideal launch site for validating new diagnostic tools as planned in the Study. Piedmont Healthcare is a not-for-profit system comprising 26 hospitals, 72 Urgent Care centers, 25 QuickCare locations, 1,875 Clinic physician practices, and nearly 3,200 physician members.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya's business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

For more information:

Corporate Enquiries

John Konstantopoulos
Co-Founder and Chief Executive Officer
Tel: +61 8 6478 7816
Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger
Hawkesbury Partners
Tel: +61 499 100 038 or +61 410 577 155
Email: investors@artrya.com